TY - JOUR
T1 - Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer
T2 - A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)
AU - Frassoldati, Antonio
AU - Guarneri, Valentina
AU - Piacentini, Federico
AU - Jovic, Gordana
AU - Giovannelli, Simona
AU - Oliva, Cristina
AU - Conte, Pier Franco
PY - 2008
Y1 - 2008
N2 - Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a crosstalk with other growth factor-related transduction pathways (mainly epidermal growth factor receptor family related). The LETLOB study is a European multicenter, placebo-controlled, randomized phase II trial in postmenopausal patients with hormone-sensitive, HER2-negative, stage II-IIIA (T > 2 cm, N0-1, M0) breast cancer, in which letrozole or the combination of letrozole plus lapatinib will be administered for 6 months before surgery. Clinical endpoints (primary [ultrasonographic objective response], secondary [rate of pathologic complete response and of conservative surgery, safety, and time to treatment failure], and biologic [inhibition of intermediate and final biomarkers of the proliferative and apoptosis pathways and gene profile correlation with response]) will be evaluated.
AB - Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a crosstalk with other growth factor-related transduction pathways (mainly epidermal growth factor receptor family related). The LETLOB study is a European multicenter, placebo-controlled, randomized phase II trial in postmenopausal patients with hormone-sensitive, HER2-negative, stage II-IIIA (T > 2 cm, N0-1, M0) breast cancer, in which letrozole or the combination of letrozole plus lapatinib will be administered for 6 months before surgery. Clinical endpoints (primary [ultrasonographic objective response], secondary [rate of pathologic complete response and of conservative surgery, safety, and time to treatment failure], and biologic [inhibition of intermediate and final biomarkers of the proliferative and apoptosis pathways and gene profile correlation with response]) will be evaluated.
KW - Mitogen-activated protein kinase
KW - Multigated acquisition scan
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=40449112910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40449112910&partnerID=8YFLogxK
U2 - 10.3816/CBC.2008.n.010
DO - 10.3816/CBC.2008.n.010
M3 - Article
C2 - 18501066
AN - SCOPUS:40449112910
VL - 8
SP - 97
EP - 100
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 1
ER -